Today: 10 June 2026
Browse Category

NASDAQ:CORT 16 December 2025 - 2 January 2026

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept shares closed down 50.4% at $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing insufficient evidence. Truist cut its price target to $50 and Wolfe downgraded the stock to Underperform with a $30 target. The FDA set a July 11, 2026 decision date for relacorilant in ovarian cancer. U.S. markets are closed Thursday for New Year’s Day.
1 January 2026
··
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics shares fell 50.4% to $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing a need for more evidence of effectiveness. The company plans to meet with the agency to discuss next steps. Wolfe Research downgraded the stock and removed projected sales for the indication. Trading volume reached about 20.16 million shares.
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept shares plunged about 50% in after-hours trading after the FDA declined to approve relacorilant for hypertension linked to hypercortisolism. The agency requested more evidence of effectiveness, despite acknowledging trial data. Wolfe Research downgraded the stock and slashed its price target. Corcept said it plans to meet with the FDA to discuss next steps.
1 January 2026
··
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept shares plunged nearly 50% to $35.31 after the FDA rejected relacorilant for Cushing’s-related hypertension, citing insufficient evidence of effectiveness. The move erased about $3.7 billion in market value. Corcept said it will meet with the FDA to discuss next steps. The company is also awaiting a July 2026 FDA decision on relacorilant in ovarian cancer.
31 December 2025
··
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics shares fell 8.9% to $72.72 in early afternoon trading Tuesday as investors awaited the FDA’s decision on relacorilant, due later in the day. SEC filings showed CEO Joseph Belanoff and Chief Business Officer Gary Charles Robb exercised stock options and withheld shares for taxes. About 897,000 shares changed hands. The drop outpaced declines in major biotech indexes.
30 December 2025
··
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics shares fell 9% to $79.44 on December 16, 2025, after UBS initiated coverage at Neutral with a $95 target, citing valuation concerns. The stock had surged about 75% year-to-date. No major clinical or regulatory news drove the drop. Trading volume reached approximately 1.27 million shares.
16 December 2025
···

Stock Market Today

  • Ordell Minerals Shares Drop Below Placement Price Amid Gold Price Decline
    June 10, 2026, 4:44 AM EDT. Ordell Minerals (ASX:ORD) shares fell 6.86% to $0.475 on June 10, 2026, trading below its $0.63 placement price from May. The decline aligns with a drop in gold prices to a two-month low, down about 23% from January's peak, impacting Australian gold stocks. Ordell, a junior gold explorer focused on Western Australia's Barimaia Gold Project, is conducting a fully funded 15,000-metre drilling program after high-grade results at McNabs East. Despite the sell-off, no new company announcements were made. Thin trading volume, with less than $16,000 exchanged by late morning, suggests sentiment-driven pressure rather than fundamental changes. Ordell's market value stands near $41.5 million, classifying it as a micro-cap stock subject to significant price moves on low turnover.

Latest articles

PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

10 June 2026
Paranovus Entertainment Technology shares jumped 19.6% premarket after filing plans for an at-the-market share sale of up to $194.99 million—an unusually large amount compared to its $1.07 million market value—raising dilution risks as the company can sell shares at prevailing prices with no minimums, while recent trading has been highly volatile and underlying operations remain limited.
Marvell Is Now in the S&P 500. The Focus Turns to Its Next Move

Marvell Is Now in the S&P 500. The Focus Turns to Its Next Move

10 June 2026
Marvell plunged 7.6% to $266.88 after Monday’s S&P 500-driven surge, as semiconductor stocks sold off despite the chipmaker’s looming June 22 index inclusion and strong AI demand; shares had soared 59% since May 27 on bullish custom-chip forecasts, but high valuation and sector volatility now threaten further gains.
ASML Shares Dip After Terafab Hype Faces EUV Shipping Hurdle

ASML Shares Dip After Terafab Hype Faces EUV Shipping Hurdle

10 June 2026
ASML shares slipped 0.44% to €1,501.80 after a sharp AI-fueled rally, as investors shift focus from Elon Musk’s Terafab praise to whether it will drive real equipment orders; with the stock up 63% this year and major analyst upgrades, July 15’s Q2 report on orders, margins, and export-control language is now the key catalyst for the next move.
Intel Shares Face Early Test After Google-Driven Spike

Intel Shares Face Early Test After Google-Driven Spike

10 June 2026
Intel shares fell 2.1% to $107.92 after Monday’s 11.2% surge on a reported Google AI-chip order, as investors weighed the unconfirmed deal’s potential to boost Intel’s foundry business against a broader tech selloff; Reuters could not verify the report, and Intel declined comment.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.06.2026

10 June 2026
LIVEMarkets rolling coverageStarted: June 10, 2026, 4:00 AM EDTUpdated: June 10, 2026, 4:45 AM EDT Ordell Minerals Shares Drop Below Placement Price Amid Gold Price Decline June 10, 2026, 4:44 AM EDT. Ordell Minerals (ASX:ORD) shares fell 6.86% to $0.475 on June 10, 2026, trading below its $0.63 placement price from May. The decline aligns with a drop in gold prices to a two-month low, down about 23% from January’s peak, impacting Australian gold stocks. Ordell, a junior gold explorer focused on Western Australia’s Barimaia Gold Project, is conducting a fully funded 15,000-metre drilling program after high-grade results at McNabs
Go toTop